Lisdexamfetamine prodrug activation by peptidase-mediated hydrolysis in the cytosol of red blood cells
Johannah Sharman, Michael Pennick Shire, Basingstoke, UK Abstract: Lisdexamfetamine dimesylate (LDX) is approved as a once-daily treatment for attention-deficit/hyperactivity disorder in children, adolescents, and adults in some countries. LDX is a prodrug comprising d-amphetamine covalently link...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2014-11-01
|
| Series: | Neuropsychiatric Disease and Treatment |
| Online Access: | http://www.dovepress.com/lisdexamfetamine-prodrug-activation-by-peptidase-mediated-hydrolysis-i-peer-reviewed-article-NDT |